This Program Announcement expires on November 30, 2004 unless reissued.


Release Date:  August 31, 2001

PA NUMBER:  PA-01-131

National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Neurological Disorders and Stroke
National Institute of Dental and Craniofacial Research



The National Institute of Arthritis and Musculoskeletal and Skin Diseases 
(NIAMS), the National Institute of Neurological Disorders and Stroke (NINDS), 
and the National Institute of Dental and Craniofacial Research (NIDCR) 
encourage investigator-initiated research grant applications on pathogenesis 
and treatment of inflammatory myopathy.  Responses to this program 
announcement may include studies in appropriate animal models or preclinical 
or clinical studies in patients with any form of inflammatory muscle disease.


The Public Health Service (PHS) is committed to achieving the health promotion 
and disease prevention objectives of "Healthy People 2010," a PHS led national 
activity for setting priority areas. This PA is related to one or more of the 
priority areas.  This program announcement, Pathogenesis and Treatment of 
Inflammatory Muscle Disease, is related to the priority area chronic disabling 
conditions.  Potential applicants may obtain a copy of "Healthy People 2010" 


Applications may be submitted by domestic and foreign for-profit and 
non-profit organizations, public and private, such as universities, colleges, 
hospitals, laboratories, units of state and local governments, and eligible 
agencies of the Federal government.  Racial/ethnic minority individuals, 
women, and persons with disabilities are encouraged to apply as principal 


The mechanism of support will be the individual research project grant (R01). 
 The Principal Investigator or program director, as well as any participating 
investigators, will plan, direct, and perform the research.  The total project 
period for an application submitted in response to this program announcement 
may not exceed five years.

Applicants must receive permission from the NIAMS, or NINDS, or NIDCR prior to 
the submission of an application requesting more than $500,000 in direct costs 
per year for any year of the proposed study.  

Investigators should contact program staff listed under INQUIRIES to discuss 
applications using other mechanisms, such as the program project grant. 



Inflammatory myopathies encompass a number of differing conditions 
(dermatomyositis, polymyositis, inclusion body myositis) characterized by 
muscle inflammation and repeated tissue degeneration and regeneration.  In 
general myositis is known to result in muscle weakness in affected 
individuals.  While myositis has been classified as an autoimmune disease, 
little is known about the etiology of this condition.  One condition, sporadic 
inclusion-body myositis (IBM), appears to share pathological features with 
some neurodegenerative disorders. IBM  demonstrates accumulations of beta/A4 
amyloid proteins similar to accumulations of amyloid in brains of Alzheimer 
disease.  Current therapies for myositis remain broad based and relatively 
nonspecific.  These include corticosteroids, cytotoxic agents, and 

Although there have been tremendous advances on the understanding of the cell 
biology, physiology and molecular genetics of skeletal muscle, there is a 
paucity of information about how the normal function of muscle cells is 
affected by inflammatory processes. Further, the contribution of the skeletal 
muscle cells or the neural innvervation of the muscle to the inflammatory 
process by either expression of surface molecules or release of soluble 
mediators or structural components that may activate an immune or inflammatory 
response is not well understood.

The National Institute of Arthritis and Musculoskeletal and Skin Diseases, the 
National Institute of Neurological Disorders and Stroke, and the Office of 
Rare Diseases of the National Institutes of Health (NIH) cosponsored a 
"Workshop on Inflammatory Myopathy." The purpose of the workshop was to 
stimulate new research on this uncommon and understudied family of diseases.  
 Investigators from around the world, representing several biomedical 
disciplines, discussed what is currently known in various disciplines relevant 
to inflammatory myopathy and suggested new areas for research support.  A 
summary of the workshop may be found at:

Scope and Objectives

The purpose of this initiative is to encourage studies on inflammatory 
myopathies and the role of inflammation in muscle disease.  Cellular processes 
should be examined, including mechanisms of cell injury and the role of 
cytokines.  It is important to define the borders between inflammatory 
myopathy and genetic dystrophies that appear clinically similar.  Since 
inflammatory cells are present in muscles in most human dystrophies, more 
research is needed on the extent to which muscle cells play a role as 
antigen-presenting cells.  There is a need for further research on the role of 
inflammation and inflammatory cells in muscular dystrophy.  It is important to 
determine if inflammatory processes interfere with repair of damaged muscle.

A goal of this initiative is to promote research that will lead to better 
treatment for inflammatory muscle disease.  Researchers are encouraged to 
propose studies aimed at developing and refining outcomes measures, studies 
looking at long term outcomes, new therapeutic interventions.  Important 
research priorities include studies on gene and stem cell therapies, 
pharmacological approaches to treatment, and clarification of inflammatory 
mechanisms in muscle.

Responses to this program announcement may include studies in appropriate 
animal models or preclinical or clinical studies in patients.  Investigators 
with diverse scientific interests are invited to apply their expertise to 
basic, applied, and clinical research to enhance our understanding of the 
pathogenesis and treatment of inflammatory muscle disease, including the 
development and sharing of appropriate resources, including animal models. 

Examples that illustrate possible areas of research are presented below.  They 
are intended only to provide a broad direction for research and should be 
considered illustrative and not restrictive.

o  Clarification of the processes by which muscle cells are damaged and 
repaired in the inflammatory myopathies. 

o  Delineation of the molecular basis for differences in repair between 
masticatory and somatic musculature.

o  Exploration of immune responses in muscle diseases.

o  Studies that establish and clarify the role of cell mediated and antibody 
mediated immune responses to muscle substances and muscle related structures.

o  Clarification of molecular and cellular aspects of tissue degeneration in 
inflammatory muscle disease.

o  Studies aimed at exploring pathogenetic mechanisms involving mitochondrial 
dysfunction and oxidative stress. 

o  Deeper exploration of the role of inflammation in genetic muscle diseases.

o  Delineation of the potential role of neurogenic influences in the origin of 
inflammatory muscle disease.

o  Studies that help define standard approaches to evaluate disease activity, 
disease damage, and clinical outcomes.

o  Studies that help develop improved diagnostic procedures.

o  Using improved imaging techniques to better understand mechanisms of 
inflammatory muscle disease and monitor treatment.

o  Exploration of new types of therapy, including gene transfer and use of 
muscle stem cells.

o  Exploration of pharmacologic interventions, including evaluations of the 
use of steroids.

o  Development, use, and sharing of appropriate animal models for inflammatory 
muscle disease.

o  Study the involvement of apoptotic cell death in the process of muscle 
fiber degeneration.

o  Explore the relationship between inflammatory cells, muscle cell death, and 
blood vessels. 


NIH policy requires education on the protection of human subject participants 
for all investigators submitting NIH proposals for research involving human 
subjects.  This policy announcement is found in the NIH Guide for Grants and 
Contracts Announcement dated June 5, 2000, at the following website:


It is the policy of the NIH that women and members of minority groups and 
their sub-populations must be included in all NIH-supported biomedical and 
behavioral research projects involving human subjects, unless a clear and 
compelling rationale and justification are provided indicating that inclusion 
is inappropriate with respect to the health of the subjects or the purpose of 
 the research.  This policy results from the NIH Revitalization Act of 1993 
(Section 492B of Public Law 103-43). 

All investigators proposing research involving human subjects should read the 
UPDATED "NIH Guidelines for Inclusion of Women and Minorities as Subjects in 
Clinical Research," published in the NIH Guide for Grants and Contracts on 
August 2, 2000 
(; a 
complete copy of the updated Guidelines are available at  The 
revisions relate to NIH defined Phase III clinical trials and require: a) all 
applications or proposals and/or protocols to provide a description of plans 
to conduct analyses, as appropriate, to address differences by sex/gender 
and/or racial/ethnic groups, including subgroups if applicable; and b) all 
investigators to report accrual, and to conduct and report analyses, as 
appropriate, by sex/gender and/or racial/ethnic group differences.


It is the policy of NIH that children (i.e., individuals under the age of 21) 
must be included in all human subjects research, conducted or supported by the 
NIH, unless there are scientific and ethical reasons not to include them.  
This policy applies to all initial (Type 1) applications submitted for receipt 
dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines on the Inclusion of Children as Participants in 
Research Involving Human Subjects" that was published in the NIH Guide for 
Grants and Contracts, March 6, 1998, and is available at the following URL 

Investigators also may obtain copies of these policies from the program staff 
listed under INQUIRIES.  Program staff may also provide additional relevant 
information concerning the policy.


All applications and proposals for NIH funding must be self-contained within 
specified page limitations.  Unless otherwise specified in an NIH 
solicitation, internet addresses (URLs) should not be used to provide 
information necessary to the review because reviewers are under no obligation 
to view the Internet sites.  Reviewers are cautioned that their anonymity may 
be compromised when they directly access an Internet site.


The Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances.  Data that are (1) first produced in a 
project that is supported in whole or in part with Federal funds and (2) cited 
publicly and officially by a Federal agency in support of an action that has 
the force and effect of law (i.e., a regulation) may be accessed through FOIA. 
 It is important for applicants to understand the basic scope of this 
amendment.  NIH has provided guidance at:

Applicants may wish to place data collected under this PA in a public archive, 
which can provide protections for the data and manage the distribution for an 
indefinite period of time.  If so, the application should include a 
description of the archiving plan in the study design and include information 
about this in the budget justification section of the application. In 
addition, applicants should think about how to structure informed consent 
statements and other human subjects procedures given the potential for wider 
use of data collected under this award.


The PHS 398 research grant application instructions and forms (rev. 5/2001) at are to be used in 
applying for these grants and will be accepted at the standard application 
deadlines ( as indicated in the 
application kit.  This version of the PHS 398 is available in an interactive, 
searchable PDF format. Although applicants are encouraged to begin using the 
5/2001 revision of the PHS 398 as soon as possible, the NIH will continue to 
accept applications prepared using the 4/1998 revision until January 9, 2002. 
Beginning January 10, 2002, however, the NIH will return applications that are 
not submitted on the 5/2001 version.  For further assistance contact 
GrantsInfo, Telephone 301/710-0267, Email:

Applicants planning to submit an investigator-initiated new (type 1), 
competing continuation (type 2), competing supplement, or any amended/revised 
version of the preceding grant application types requesting $500,000 or more 
in direct costs for any year are advised that he or she must contact the 
Institute or Center (IC) program staff before submitting the application, 
i.e., as plans for the study are being developed.  Furthermore, the 
application must obtain agreement from the IC staff that the IC will accept 
the application for consideration for award.  Finally, the applicant must 
identify, in a cover letter sent with the application, the staff member and 
Institute or Center who agreed to accept assignment of the application.  This 
policy requires an applicant to obtain agreement for acceptance of any such 
application and any such subsequent amendment.  Refer to the NIH Guide for 
Grants and Contracts, March 20, 1998 at


The modular grant concept establishes specific modules in which direct costs 
may be requested as well as a maximum level for requested budgets. Only 
limited budgetary information is required under this approach.  The just-in-
time concept allows applicants to submit certain information only when there 
is a possibility for an award. It is anticipated that these changes will 
reduce the administrative burden for the applicants, reviewers and NIH staff. 
 The research grant application form PHS 398 (rev. 5/2001) at is to be used in 
applying for these grants, with modular budget instructions provided in 
Section C of the application instructions.  Applicants are permitted, however, 
to use the 4/1998 revision of the PHS 398 for scheduled application receipt 
dates until January 9, 2002.  If you are preparing an application using the 
4/1998 version, please refer to the step-by-step instructions for Modular 
Grants available at  Additional 
information about Modular Grants is also available on this site.


The title (Pathogenesis and Treatment of Inflammatory Muscle Disease) and 
number of the program announcement must be typed on line 2 of the face page of 
the application form and the YES box must be marked. 

Submit a signed, typewritten original of the application, including the 
Checklist, plus five signed photocopies, in one package to: 

6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD  20892-7710
BETHESDA, MD  20817 (for express/courier service)


Applications will be assigned on the basis of established PHS referral 
guidelines.  Applications will be evaluated for scientific and technical merit 
by an appropriate scientific review group convened in accordance with the 
standard NIH peer review procedures.  As part of the initial merit review, all 
applications will receive a written critique and undergo a process in which 
only those applications deemed to have the highest scientific merit, generally 
the top half of applications under review, will be discussed, assigned a 
priority score, and receive a second level review by the appropriate national 
advisory council or board.

Review Criteria

The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health.  In 
the written review, comments on the following aspects of the application will 
be made in order to judge the likelihood that the proposed research will have 
a substantial impact on the pursuit of these goals.  Each of these criteria 
will be addressed and considered in the assignment of the overall score.  Note 
that the application does not need to be strong in all categories to be judged 
likely to have major scientific impact and thus deserve a high priority score. 
 For example, an investigator may propose to carry out important work that by 
its nature is not innovative but is essential to move a field forward.

o  Significance: Does this study address an important problem?  If the aims of 
the application are achieved, how will scientific knowledge be advanced?  What 
will be the effect of these studies on the concepts or methods that drive this 

o  Approach: Are the conceptual framework, design, methods, and analyses 
adequately developed, well integrated, and appropriate to the aims of the 
project? Does the applicant acknowledge potential problem areas and consider 
alternative tactics?

o  Innovation: Does the project employ novel concepts, approaches or methods? 
Are the aims original and innovative?  Does the project challenge existing 
paradigms or develop new methodologies or technologies?

o  Investigator: Is the investigator appropriately trained and well suited to 
carry out this work?  Is the work proposed appropriate to the experience level 
of the principal investigator and other researchers (if any)? 

o  Environment: Does the scientific environment in which the work will be done 
contribute to the probability of success?  Do the proposed experiments take 
advantage of unique features of the scientific environment or employ useful 
collaborative arrangements?  Is there evidence of institutional support? 

In addition to the above criteria, in accordance with NIH policy, all 
applications will also be reviewed with respect to the following:

o  The adequacy of plans to include both genders, minorities and their 
subgroups, and children as appropriate for the scientific goals of the 
research.  Plans for the recruitment and retention of subjects will also be 

o  The reasonableness of the proposed budget and duration in relation to the 
proposed research.

o  The adequacy of the proposed protection for humans, animals or the 
environment, to the extent they may be adversely affected by the project 
proposed in the application.

o  Review of grants with foreign components will consider availability of 
special opportunities for furthering research programs through the use of 
unusual talent resources, populations, or environmental conditions in other 
countries which are not readily available in the United States or which 
provide augmentation of existing United States resources.


Applications will compete for available funds with all other recommended 
applications.  The following will be used in making funding decisions: 

o  Scientific and technical merit of the proposed project as determined by 
peer review

o  Availability of funds

o  Program balance among research areas of the announcement 

NIAMS funding policy may be seen at:  NINDS funding strategy may be 
found at:


Inquiries concerning this PA are encouraged.  The opportunity to clarify any 
issues or questions from potential applicants is welcome.

Direct inquiries regarding programmatic and scientific issues to one of the 
following persons: 

Richard W. Lymn, Ph.D.
Muscle Biology Program
National Institute of Arthritis and Musculoskeletal and Skin Diseases
45 Center Drive, Room 5AS-49E
Bethesda, MD  20892-6500
Telephone:  (301) 594-5128
FAX:  (301) 480-4543

Susana Serrate-Sztein, M.D.
Rheumatic Diseases Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
45 Center Drive, Natcher Bldg. Rm. 5A25
Bethesda MD  20892-6500
Telephone:  (3101) 594-5032
FAX:  (301) 480-4543

A. P. Kerza-Kwiatecki, Ph.D.
Program Director
NSC, Rm. 2115
6001 Executive Blvd., 
Bethesda, MD  20892-9521
(For courier service only use: Rockville, MD 20852)
Phone:  301-496-1431
FAX:  301-402-2060
E-mail:  AK45W@NIH.GOV

Dr. Guo Zhang
Program Director
Division of Extramural Research
National Institute of Dental and Craniofacial Research
Natcher Building, Room 4AN-18C
Bethesda, MD  20892-6402
Telephone:  (301) 594-0618
FAX:  (301) 480-8318

Direct inquiries regarding fiscal matters to:

Melinda Nelson
Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin Diseases
45 Center Drive, Room 5AS-49F, MSC 6500
Bethesda, MD  20892-6500
Telephone:  (301) 594-3535
FAX:  (301) 480-5450

Dianna Jessee
Grants Management Branch
National Institute of Neurological Disorders and Stroke
Neuroscience Center, Room 3290
6001 Executive Boulevard
Bethesda, MD  20892-9537 
Telephone:  (301) 496-7416
FAX:  (301) 402-0219

Mr. Martin Rubinstein
Office of Grants Management
National Institute of Dental and Craniofacial Research
Natcher Building, Room 4AN-44A
Bethesda, MD  20892-6402
Telephone:  (301) 594-4800
FAX:  (301) 480-8301


This program is described in the Catalog of Federal Domestic Assistance No. 
93.846 (NIAMS), No. 93.853 (NINDS), and No. 93.121 (NIDCR).  Awards are made 
under authorization of sections 301 and 405 of the Public Health Service Act 
as amended (42 USC 241 and 284) and administered under NIH grants policies and 
Federal Regulations 42 CFR 52 and 45 CFR Parts 74 and 92.  This program is not 
subject to the intergovernmental review requirements of Executive Order 12372 
or Health Systems Agency review.

The PHS strongly encourages all grant and contract recipients to provide a 
smoke free workplace and promote the non-use of all tobacco products.  In 
addition, Public law 103-227, the pro-Children Act of 1994, prohibits smoking 
in certain facilities (or in some cases, any portion of a facility) in which 
regular or routine education, library, day care, health care or early 
childhood development services are provided children.  This is consistent with 
the PHS mission to protect and advance the physical and mental health of the 
American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.